Your thoughts were, in my opinion, very much the motiviation for management last year to hire Tina as a consultant in SF to expose us to a broader client base in life sciences and smaller IVD companies in the US.
The latest life science signing was, as I see it, a direct consequence of this step which will lead us within the next 2 quarterlies to be a cash positive company.
A CEO has to counterweigh the costs of increased staff with the commercial outlook out of all pipeline activities. To spread staff onto too many projects or amongst possible clients or partners, or even hire additional staff to fill positions might be too risky for a company in its early stages of commercialisation. It would counterproductive.
I therefore agree with management's decision to secure a few smaller signings within the life science sector ( the possible Danaher link I previously referred to would be not quite so small indeed ) whilst waiting for a larger signature from within the IVD sector to allow consequently a push into new applied fields for our technology from a financially strong position which allows to dictate terms inaccessable at current status.
ADO Price at posting:
7.2¢ Sentiment: LT Buy Disclosure: Held
